Analyzing Auxilium Pharmaceuticals (AUXL) and Its Competitors
Auxilium Pharmaceuticals (NASDAQ: AUXL) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Auxilium Pharmaceuticals to similar companies based on the strength of its profitability, risk, earnings, valuation, dividends, analyst recommendations and institutional ownership.
Volatility and Risk
Auxilium Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals’ rivals have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Auxilium Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxilium Pharmaceuticals Competitors||137||801||1761||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 12.23%. Given Auxilium Pharmaceuticals’ rivals higher possible upside, analysts clearly believe Auxilium Pharmaceuticals has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
43.5% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Auxilium Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxilium Pharmaceuticals Competitors||-13,603.82%||-109.96%||-27.55%|
Earnings and Valuation
This table compares Auxilium Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auxilium Pharmaceuticals Competitors||$564.12 million||$96.17 million||65.24|
Auxilium Pharmaceuticals’ rivals have higher revenue and earnings than Auxilium Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Auxilium Pharmaceuticals rivals beat Auxilium Pharmaceuticals on 5 of the 8 factors compared.
About Auxilium Pharmaceuticals
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.